Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 8 for:    ialuril

The Efficacy of Additional Intravesical Instillation of Hyaluronic Acid/Chondroitin Sulfate to Transurethral Resection of Bladder Ulcer in Patients With Interstitial Cystitis/Bladder Pain Syndrome.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01813565
Recruitment Status : Terminated (No benefit of intravesical instillation of Hyaluronic Acid/Chondroitin Sulfate)
First Posted : March 19, 2013
Last Update Posted : July 4, 2019
Sponsor:
Information provided by (Responsible Party):
Myung-Soo Choo, Asan Medical Center

Brief Summary:
The purpose of this study is to evaluate efficacy and safety of additional hyaluronic acid/chondroitin sulfate to transurethral resection of bladder ulcer in patient with interstitial cystitis.

Condition or disease Intervention/treatment Phase
Interstitial Cystitis Drug: Hyaluronic acid/chondroitin sulfate Not Applicable

Detailed Description:
This is a randomized, parallel, 6 month period study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Efficacy of Additional Intravesical Instillation of Hyaluronic Acid/Chondroitin Sulfate to Transurethral Resection of Bladder Ulcer in Patients With Interstitial Cystitis/Bladder Pain Syndrome.
Actual Study Start Date : March 20, 2013
Actual Primary Completion Date : December 1, 2016
Actual Study Completion Date : December 1, 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Additional instillation of hyaluronic acid/chondroitin sulfate
Transurethral resection of bladder ulcer + instillation of hyaluronic acid/chondroitin sulfate
Drug: Hyaluronic acid/chondroitin sulfate
Additional Hyaluronic acid/chondroitin sulfate instillation to the bladder
Other Name: Ialuril

Active Comparator: Transurethral resection of bladder ulcer
Transurethral resection of bladder ulcer
Drug: Hyaluronic acid/chondroitin sulfate
Additional Hyaluronic acid/chondroitin sulfate instillation to the bladder
Other Name: Ialuril




Primary Outcome Measures :
  1. Change of pain scores on the Visual Analogue Scale [ Time Frame: 1month, 3month, 6month ]
    Change of pain scores on the Visual Analogue Scale


Secondary Outcome Measures :
  1. Duration of symptom improvement [ Time Frame: 1month, 3month, 6month ]
    Duration of symptom improvement

  2. Changes of frequency and urgency on voiding diary [ Time Frame: 1month, 3month, 6month ]
    Changes of frequency and urgency on voiding diary

  3. Change score of O'Leary-Sant Interstitial Cystitis questionnaire (IC-Q) [ Time Frame: 1month, 6month ]
    Change score of O'Leary-Sant Interstitial Cystitis questionnaire (IC-Q)

  4. Score of Global Response Assessment (GRA), Patient Global Assessment (PGA) score [ Time Frame: 6month ]
    Score of Global Response Assessment (GRA), Patient Global Assessment

  5. Occurrence of adverse event [ Time Frame: 6month ]
    Occurrence of adverse event

  6. Change score of Pelvic Pain and Urgency/Frequency Patient Symptom Scale(PUF) [ Time Frame: 1month, 6month ]
    Change score of Pelvic Pain and Urgency/Frequency Patient Symptom Scale

  7. Change score of EQ-5D Health Questionnaire [ Time Frame: 1month, 6month ]
    Change score of EQ-5D Health Questionnaire

  8. Change score of Brief Pain Inventory-short form (BPI-sf) [ Time Frame: 1month, 6month ]
    Change score of Brief Pain Inventory-short form (BPI-sf)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. must have experienced bladder pain, urinary urgency and urinary frequency, for at least 6 months prior to entry into the study
  2. Pain VAS ≥4
  3. O'Leary-Sant Interstitial Cystitis questionnaire (IC-Q) symptom and problem ≥ 12( and pain ≥2, and nocturia ≥ 2)
  4. PUF score ≥ 13
  5. cystoscopic record within 2 years
  6. Hunner ulcer lesion in cystoscopic finding

Exclusion Criteria:

  1. Scheduled for or use of intravesical therapy (eg, bladder distention,transurethral resection of bladder ulcer, instillation) during or within 6months prior to the study and use of pentosan polysulfate sodium within 1 months prior to the study
  2. Patients who are pregnancy or, childbearing age without no contraception
  3. Patients with voided volume <40 or, > 400ml
  4. Patients with microscopic hematuria, (≥1+ in dipstick), If not excluded that no evidence of neoplastic tumor examination
  5. Patients with urine culture showing evidence of urinary tract infection 1month prior to the study
  6. Accompanied medical problem below

    • Tuberculosis in urinary system
    • Bladder cancer, urethral cancer, prostate cancer
    • Recurrent cystitis
    • anatomical disorder
  7. Patients had prior surgery (eq, bladder augmentation, cystectomy
  8. Patients with neurologic disorder
  9. Patients with indwelling catheter or intermittent self-catheterization
  10. Patients with psychologic problem

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01813565


Locations
Layout table for location information
Korea, Republic of
Asan medical center
Seoul, Korea, Republic of
Sponsors and Collaborators
Asan Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Myung -Soo Choo, profesor Asan Medical Center

Layout table for additonal information
Responsible Party: Myung-Soo Choo, Profesor, Asan Medical Center
ClinicalTrials.gov Identifier: NCT01813565     History of Changes
Other Study ID Numbers: 20130135
First Posted: March 19, 2013    Key Record Dates
Last Update Posted: July 4, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cystitis
Cystitis, Interstitial
Urinary Bladder Diseases
Urologic Diseases
Hyaluronic Acid
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Viscosupplements
Protective Agents